Study of F527 in Patients With Relapsed or Refractory Lymphoma
This study is a non-randomized, open-label, phase I dose-finding and dose-expansion study to evaluate the safety, tolerability, antitumor efficacy, PK and immunogen of F527 in patients with relapsed or refractory lymphoma sexual characteristics.
Relapsed/Refractory Lymphoma
DRUG: F527
DLTs, Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period, Up to 21 days|Maximum Tolerated Dose (MTD), Maximum Tolerated Dose, Up to 21 days|RP2D, PR2D will be determined by the sponsor and investigator based on the comprehensive data obtained on drug safety and tolerability, PK, preliminary anti-tumor efficacy, etc., Up to 21 days
This study is a non-randomized, open-label, phase I dose-finding and dose-expansion study to evaluate the safety, tolerability, antitumor efficacy, PK and immunogen of F527 in patients with relapsed or refractory lymphoma sexual characteristics.